On July 15 we reviewed the charts of medical device maker DexCom (DXCM) and wrote that "Aggressive traders could probe the long side of DXCM around current levels. Risk to $72. Maybe we can rally to the $100 area."
More from Investing
We now have worries about the Fed raising rates while bonds are acting like the economy is going to slow dramatically.
Let's uncover the Alpha Architect Inflation and Deflation exchange-traded fund.
The shares have recently failed at the underside of the declining 200-day moving average line.
We have a price target for this infrastructure engineering software firm.
This is typical bear market action in which stock picking doesn't matter much, and macro considerations are driving the indexes -- still, I've got a pick.